Investor Presentation

Verici Dx PLC

20 November 2023

 

Verici Dx plc

("Verici Dx" or the "Company")

Investor Presentation

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Sara Barrington, CEO, will provide a live presentation relating to the Company's recent global licensing and commercialisation agreement for its pre-transplant test (Clarava™) with Thermo Fisher Scientific (https://verici-dx-plc.flint-platform.com/regulatory-news/44270), via the Investor Meet Company platform on 22 November 2023 at 17.00 (GMT).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

Investors who already follow VERICI DX PLC on the Investor Meet Company platform will automatically be invited.

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher / Jalini Kalaravy
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen	Mob: [phone]

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END